MedPath

BMN-349

Generic Name
BMN-349

Study of BMN 349 Single Dose in (PiZZ) and (PiMZ) Adult Participants

Phase 1
Recruiting
Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
Drug: Placebo
First Posted Date
2024-12-17
Last Posted Date
2025-03-17
Lead Sponsor
BioMarin Pharmaceutical
Target Recruit Count
12
Registration Number
NCT06738017
Locations
🇺🇸

University of California, San Diego, San Diego, California, United States

🇺🇸

Saint Louis University, Saint Louis, Missouri, United States

🇺🇸

Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States

and more 1 locations
© Copyright 2025. All Rights Reserved by MedPath